Ezetimibe - Cholesterol Absorption Inhibitor for Dyslipidemia / Articles

Introduction

Ezetimibe is a first-in-class lipid-lowering agent that reduces cholesterol levels by selectively inhibiting the intestinal absorption of dietary and biliary cholesterol. Unlike statins, which reduce cholesterol synthesis in the liver, ezetimibe acts at the level of the intestinal enterocyte, blocking the absorption of cholesterol without affecting the absorption of fat-soluble vitamins or triglycerides. This unique mechanism of action makes ezetimibe a valuable therapeutic option for patients with primary hyperlipidemia, either as monotherapy in individuals who cannot tolerate statins or in combination with statins for additive LDL cholesterol reduction. Ezetimibe is also indicated for the treatment of homozygous sitosterolemia, a rare genetic disorder characterized by elevated plasma sitosterol levels.

Chemical and Physical Properties

Ezetimibe is a synthetic azetidinone derivative with the molecular formula C₂₄H₂₁F₂NO₃ and a molecular weight of 409.43 g/mol. Key physical and chemical parameters include:

CAS Number: 163222-33-1
Molecular formula: C₂₄H₂₁F₂NO₃
Molecular weight: 409.43 g/mol
Chemical name: (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
Appearance: White to off-white crystalline powder
Solubility: Practically insoluble in water; soluble in organic solvents (ethanol, methanol, dimethyl sulfoxide)
Stability: Stable under normal storage conditions

Mechanism of Action

Ezetimibe exerts its lipid-lowering effect through selective inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) protein, a multipass transmembrane transporter located on the apical membrane of intestinal enterocytes. NPC1L1 is a critical mediator of intestinal cholesterol absorption, facilitating the uptake of both dietary and biliary cholesterol.

Ezetimibe binds to NPC1L1 with high affinity (Ki = 220 nM) and blocks cholesterol transport by occluding the transport tunnel rather than competing with cholesterol binding. This inhibition prevents the internalization of cholesterol into enterocytes, reducing the delivery of cholesterol to the liver via chylomicrons. The reduced hepatic cholesterol pool leads to compensatory upregulation of LDL receptors, enhancing the clearance of LDL cholesterol from the bloodstream.

In addition to its primary action in the intestine, ezetimibe has been shown to increase extrahepatic reverse cholesterol transport, promoting cholesterol efflux from peripheral tissues.

Pharmacokinetics and Metabolism

After oral administration, ezetimibe is rapidly absorbed and extensively metabolized (>80 %) in the small intestine and liver via glucuronide conjugation, a phase II metabolic reaction, producing a pharmacologically active phenolic glucuronide. Both ezetimibe and its glucuronide conjugate are potent inhibitors of NPC1L1, contributing to the sustained pharmacological effect.

Key pharmacokinetic parameters include:

Peak plasma concentration (Cmax): Ezetimibe-glucuronide reaches Cmax in 1–2 hours; ezetimibe in 4–12 hours
Bioavailability: Rapid and extensive absorption following oral administration
Half-life: Both ezetimibe and ezetimibe-glucuronide have an elimination half-life of approximately 22 hours
Excretion: Biliary and renal excretion of the glucuronide conjugate
Plasma protein binding: High (approximately 90 %)

Clinical Applications

Clinical studies have demonstrated the efficacy of ezetimibe in reducing LDL cholesterol across various patient populations:

Primary Hyperlipidemia: The recommended dose of ezetimibe is 10 mg orally once daily, with or without food. As monotherapy, ezetimibe lowers LDL cholesterol by approximately 18–20 %. When combined with a statin, it provides an additional 15–20 % reduction beyond that achieved with statin monotherapy.

Combination Therapy: In patients with mixed hyperlipidemia, ezetimibe coadministered with fenofibrate significantly lowers total cholesterol, LDL cholesterol, apolipoprotein B, and non-HDL cholesterol. Ezetimibe combined with simvastatin or atorvastatin reduces LDL cholesterol by 21 % compared to increasing the statin dose from 40 mg to 80 mg (7 %).

Familial Hypercholesterolemia: Ezetimibe is indicated for use in combination with a statin in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH).

Homozygous Sitosterolemia: Ezetimibe is indicated for the treatment of homozygous sitosterolemia, a rare genetic disorder characterized by elevated plasma sitosterol levels (>5 mg/dL).

Cardiovascular Outcomes: Systematic reviews have demonstrated that ezetimibe significantly reduces major adverse cardiovascular events (median RR = 0.93).

Safety and Toxicology

Ezetimibe is generally well-tolerated, with a safety profile comparable to placebo. Key safety considerations include:

Common Adverse Effects (≥2 % incidence):

Upper respiratory tract infection
Headache
Joint pain and pain in arms or legs
Flu-like symptoms and diarrhea
Myalgia

Serious Adverse Effects (rare):

Hepatotoxicity: Elevated liver enzymes can occur in patients taking ezetimibe alone or with statins
Myopathy and rhabdomyolysis: Unexplained muscle pain, tenderness, or weakness should be reported immediately
Severe cutaneous adverse reactions: Including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome have been reported
Allergic reactions: Including angioedema (swelling of the face, tongue, or throat)

Drug Interactions:

Cyclosporine: May increase ezetimibe exposure
Fibrates: Coadministration with fenofibrate may increase the risk of gallbladder disease
Bile acid sequestrants: Administer ezetimibe at least 2 hours before or 4 hours after bile acid sequestrants to avoid interference with absorption
Warfarin: Monitor INR when ezetimibe is added to warfarin therapy

Contraindications: Ezetimibe is contraindicated in patients with a history of hypersensitivity to ezetimibe or any component of the formulation. It should be used with caution in patients with moderate to severe hepatic impairment.

Pregnancy and Lactation: Ezetimibe should be used during pregnancy only if clearly needed. It is not known whether ezetimibe is excreted in human milk; caution should be exercised when administered to nursing women.

Storage and Handling

To maintain product integrity and ensure safe use:

Temperature: Store at 20–25 °C (68–77 °F); excursions permitted to 15–30 °C (59–86 °F)
Protection: Protect from moisture
Container: Store in tightly sealed, original containers
Shelf life: Tablets typically have a shelf life of 24–36 months when stored under recommended conditions. Bulk powder should be stored at –20 °C in lyophilized form for long-term stability (up to 36 months)
Incompatibilities: Avoid contact with strong oxidizing agents
Spills: Sweep up or vacuum to avoid dust generation. Dispose in accordance with local environmental regulations

Conclusion

Ezetimibe (CAS 163222-33-1, C₂₄H₂₁F₂NO₃) represents a major advance in lipid-lowering therapy through its unique mechanism of intestinal cholesterol absorption inhibition. By selectively blocking the NPC1L1 transporter, ezetimibe reduces LDL cholesterol by 18–20 % as monotherapy and provides additive reductions when combined with statins. Its favorable safety profile, convenient once-daily dosing, and demonstrated efficacy in reducing cardiovascular events have established ezetimibe as an important therapeutic option for the management of dyslipidemia. Ongoing research continues to explore its potential in combination with novel lipid-lowering agents, including PCSK9 inhibitors and CETP inhibitors, promising further improvements in cardiovascular risk reduction for patients with hypercholesterolemia.